InsidersTradesSigma
Total declarations
Companies
▲ Purchases (1 ops.)
▼ Sales (0 ops.)
Insider track record
CEODisclosed buys
1
Disclosed sells
0
T+90 hit rate
14%
T+90 mean return
-15.8%
Across 7 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Explore the complete record of transactions filed by Blanchard Cheryl R, Présidente et Directrice Générale. Insider active across 3 companies, notably Anika Therapeutics, Inc.. In total, 14 reports have been recorded. Split: 1 buy · 0 sell. Total volume traded: €99k. History available since 15 June 2021. The latest transaction was disclosed on 22 May 2025 (Attribution). Regulator: SEC (Form 4). All data is openly available.
Declarations14 total
5,000 shares0Common StockSEC:0000950170-25-077268:0
25,132 shares0Common StockSEC:0001171843-25-001531:0
30,060 shares0Common StockSEC:0001171843-25-001467:0
5,871 shares@ US$16.6252.1% of flowCommon StockSEC:0001171843-25-001404:1
20,002 shares0Common StockSEC:0001171843-25-001404:0
14,420 shares0Common StockSEC:0001171843-24-001307:0
24,575 shares0Common StockSEC:0001171843-23-002685:0
30,060 shares0Common StockSEC:0001171843-23-001684:0
14,419 shares0Common StockSEC:0001171843-23-001595:0
24,576 shares0Common StockSEC:0001171843-22-002980:0
4,287 shares@ US$25.3590.050% mcap54.5% of flowCommon StockSEC:0001171843-22-001833:0
Ideal exit: 6 Dec 2022 (T+270)
14,420 shares0Common StockSEC:0001171843-22-001809:0
2,994 shares@ US$33.4047.9% of flowCommon StockSEC:0001171843-21-004397
2,994 shares@ US$33.400.042% mcap45.5% of flowCommon StockSEC:0001171843-21-004397:0
14 of 14 declarations
About Blanchard Cheryl R
Cheryl R. Blanchard is President and CEO of Anika Therapeutics, Inc. She leads the strategic and operational activities of the company, focusing on innovation and product development. Her leadership is essential in achieving Anika's growth objectives.
